Table 1 Demographic, clinical and prognostic characteristics of early clinical stage CLL patients
Characteristics | n = 14 |
|---|---|
Male | |
  n (%) | 11 (79) |
Age (years) | |
 Median (Min., Max.) | 71 (60, 89) |
Rai Clinical stage 0 | |
  n (%) | 14 (100) |
Absence of B symptomatology | |
  n (%) | 12 (86) |
CNS disease | |
  n (%) | 0 |
Hemoglobin (gr/dL) | |
 Median (Min., Max.) | 14.6 (10.0, 17.1) |
Platelet count (X103 per microliter) | |
 Median (Min., Max.) | 171 (128, 257) |
Lymphocyte count (X103 per microliter) | |
 Median (Min., Max.) | 12.2 (4.0, 58.2) |
Overexpression of CD38 | |
  n (%) | 3 (21) |
Presence of IgVH hypermutation | |
  n (%) | 2 (14) |
Cytogenetic abnormalities: n (%) | |
 13q deletion | 4 (29) |
 Trisomy 12 | 1 (7) |
 17p deletion | 1 (7) |
Follow-up duration from diagnosis (months) | |
 Median (Min., Max.) | 74.8 (32.5, 188.6) |
Progression to treatment | |
  n (%) | 3 (21) |
Time to progression from diagnosis (months) | |
 Median (Min., Max.) | 59.1 (11.4, 66.5) |